Identification of an age-dependent biomarker signature in children and adolescents with autism spectrum disorders

Jordan M Ramsey1, Paul C Guest1, Jantine AC Broek1, Jeffrey C Glennon2, Nanda Rommelse3,4, Barbara Franke3,5, Hassan Rahmoune1, Jan K Buitelaar3,4 and Sabine Bahn1,6*

Abstract

Background: Autism spectrum disorders (ASDs) are neurodevelopmental conditions with symptoms manifesting before the age of 3, generally persisting throughout life and affecting social development and communication. Here, we have investigated changes in protein biomarkers in blood during childhood and adolescent development.

Methods: We carried out a multiplex immunoassay profiling analysis of serum samples from 37 individuals with a diagnosis of ASD and their matched, non-affected siblings, aged between 4 and 18 years, to identify molecular pathways affected over the course of ASDs.

Results: This analysis revealed age-dependent differences in the levels of 12 proteins involved in inflammation, growth and hormonal signaling.

Conclusions: These deviations in age-related molecular trajectories provide further insight into the progression and pathophysiology of the disorder and, if replicated, may contribute to better classification of ASD individuals, as well as to improved treatment and prognosis. The results also underline the importance of stratifying and analyzing samples by age, especially in ASD and potentially other developmental disorders.

Keywords: Autism, Age, Biomarkers, Molecular profiling, Inflammation, Metabolism

Background

Autism spectrum disorders (ASDs) are a clinically and biologically heterogeneous group of neurodevelopmental conditions characterized by a triad of core features: social and communication impairments and restricted repetitive behavior. The clinical manifestations of ASD have been shown to change over development. Cross-sectional and longitudinal research indicates that the severity of the core features and maladaptive behaviors of ASD among adolescents and adults tend to abate with age [1-4]. A cross-sectional study showed improved gaze behavior and social functioning of ASD subjects between adolescence and adulthood, with the suggestion that increased mirror neuron system activity may contribute to these effects [5].

In addition to the clinical manifestations, there is accumulating evidence that individuals with ASD have significant differences in brain development compared to controls. The results of several studies that were reviewed in [6] have shown there is reduced functional activation in multiple brain areas of 2-to 4-year-old children during socio-emotional, cognitive and attention tasks. Also, studies have shown age-dependent changes in cortical development [7] in brain regions involved in social-cognitive and motor function [8], language [9], and symptom severity [10]. Taken together, the findings indicate that neurobiological alterations that occur during the first years of life may underlie the neuroanatomical, functional and behavioral aspects of ASD. Therefore, identification of biomarkers associated with these alterations may provide further insights into the disease etiology.

* Correspondence: sb209@cam.ac.uk
1Department of Chemical Engineering and Biotechnology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QT, UK
2Department of Neuroscience, Erasmus Medical Centre, ’s-Gravendijkwal 230, Rotterdam 3015 CE, The Netherlands
Full list of author information is available at the end of the article

© 2013 Ramsey et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Thus far, there have been only a small number of studies that have attempted to identify molecular changes in ASD that occur at different ages. One study found age-dependent gene expression changes in prefrontal cortex using whole-genome analysis of mRNA levels in post-mortem brains of ASD subjects. Most of the molecular profiling studies have investigated age-related changes in ASD subjects in the levels of growth factors such as brain-derived neurotrophic factor (BDNF). In ASD cases, the levels of BDNF were found to be significantly lower in 0- to 9-year-old children compared to those aged greater than 10 years, while no age-related differences in BDNF levels were found for non-ASD controls. This suggested that there may be a delayed increase of BDNF with development. The 1H nuclear magnetic resonance (NMR) analyses found lower frontal lobe ratios of N-acetylaspartate/creatine, which was correlated with age in ASD children. This could reflect increased mitochondrial metabolism and may be related to symptoms of obsessional behavior and decreased social function of the patients.

Most previous molecular profiling studies of ASD have been performed using specific age groups, which precludes identification of changes that occur at different stages of development. Here we have attempted to gain further insight into age-related molecular trajectories in ASD by multiplex immunoassay profiling of 208 analytes in serum from patients and sibling controls, following partitioning into three age groups (4 to 9, 9 to 13 and 13 to 18 years). This platform has the advantage of being capable of screening multiple molecules simultaneously in biological samples and has been used previously to identify serum or plasma biomarkers in several areas of medicine, including neuropsychiatric conditions such as schizophrenia, bipolar disorder, major depressive disorder and Asperger syndrome.

Methods
Subjects
Subjects were recruited from Karakter Child and Adolescent Psychiatry and the Radboud University Nijmegen Medical Center in Nijmegen, The Netherlands. The subjects included 37 ASD subjects (age = 10.8 ± 3.5 years; body mass index (BMI) = 18.0 ± 3.7 kg/m²) and 37 controls (age = 10.5 ± 3.2 years; BMI = 17.6 ± 3.0 kg/m²). Diagnosis of ASD was confirmed by a structured developmental interview with the parents (ADI-R). Subjects with a diagnosis of autistic disorder (AD) or pervasive developmental disorder—not otherwise specified (PDD-NOS) were included in the study. The Wechsler Abbreviated Scale of Intelligence was administered to all participants to measure intelligence quotient, and age-appropriate Autism Spectrum Quotient (AQ) questionnaires were recorded for all ASD and control individuals. All diagnoses and clinical tests were performed by psychiatrists under Good Clinical Practice compliance to minimize variability. Unaffected control subjects were siblings recruited from the same families and had comparable age, gender and body mass index (BMI) to the respective patient populations.

Samples
Blood samples were collected from all ASD individuals and controls into S-Monovette 7.5 mL serum tubes (Sarstedt, Numbrecht, Germany). Serum was prepared using standard protocols by leaving samples at room temperature for 2 hours to allow clotting, followed by centrifugation at 4,000 × g for 5 minutes to remove clotted cells and other particulate material. The resulting supernatants were stored at −80°C in LoBind Eppendorf tubes (Hamburg, Germany). The study protocols, processing of clinical samples and execution of test methods were carried out in compliance with the Standards for Reporting of Diagnostic Accuracy (STARD) initiative.

Multiplex immunoassay analysis
The levels of 256 initial analytes were measured in 250 μL serum using multiplexed immunoassays (Discovery MAP™ platform) in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory (Myriad-RBM; Austin, TX, USA) as described previously. Briefly, samples were analyzed at optimized dilutions and raw intensity measurements were converted into absolute protein concentrations using duplicate 8-point standard curves. Sample analysis was randomized to minimize bias due to measurement-related effects.

Statistical analysis
The statistical programming software R (http://www.r-project.org/) was used to pre-process, analyze and plot the multiplex immunoassay data. First, the data were filtered to remove those assays with more than 30% of values lying outside the limits of quantitation. This resulted in exclusion of 48 assays. For the remaining 208 analytes, low values were replaced by 0.5 X the corresponding minimum values for that assay and high readings were replaced by 2.0 X the maximum levels. For each assay, values were loge transformed for analysis,
and outlying values were removed if these exceeded more than 3 standard deviations from the means. Deviations from typical molecular developmental patterns in ASD siblings were assessed by calculating age-diagnosis interactions. The interaction was assessed using a linear model, adjusting for additional covariates of family membership, plate, BMI, and sex. A similar procedure was used to identify molecules changed in ASD, adjusting for these same additional covariates in a linear model. Next, relationships between molecules with significant age-diagnosis interactions were tested by computing Spearman rank correlation coefficient between each pair of molecules for control siblings using untransformed data. Statistical tests were deemed significant at \( P < 0.05 \).

**In-silico pathway analysis**

The UniProt accession codes of proteins which showed diagnosis-age interactions were uploaded into the Ingenuity Pathways Knowledge Database (IPKB; Ingenuity Systems; Mountain View, CA, USA). Pathways most significant to the data set were determined by overlaying the identified proteins onto predefined pathway maps in the IPKB. A right-tailed Fisher’s exact test was used to calculate \( P \) values associated with the identified pathways. The significance of the association between the dataset and canonical pathways was measured by the ratio of the number of significant molecules divided by the total number of molecules in the canonical pathway and by the Fisher’s exact test \( P \) value.

**Results**

**Identification of altered molecules in autism spectrum disorder individuals compared to sibling controls**

Multiplex immunoassay analysis of all ASD individuals (\( n = 37 \)) and controls (\( n = 37 \)) resulted in identification of nine proteins which were present at significantly different levels ( interleukin-3, interleukin 12 subunit p40, interleukin-13, macrophage derived chemokine, stem cell factor, Tamm-Horsfall urinary glycoprotein, tumor necrosis factor beta, tyrosine kinase with Ig and EGF homology domains 2 and von Willebrand factor) (Table 1). None showed a difference higher than 1.2-fold or less than 0.8-fold. We next determined whether molecular differences between ASD and control individuals were potentially obscured by the age range investigated.

**Identification of molecules which showed diagnosis-age interactions**

The investigated individuals were separated into age groups approximating time periods before (<9 years), during (9 to 13 years) and after (>13 years) puberty (Table 2). ASD subjects and their unaffected control siblings did not differ significantly in mean age, body mass index (BMI), height or weight values. AQ scores were significantly different (\( P < 0.05 \)) between ASD and unaffected individuals. AQ scores did not change significantly with age for ASD individuals or for controls. Deviations from typical molecular developmental patterns in ASD subjects were assessed by calculating an age-diagnosis interaction using a linear model, as described in the Materials and Methods section. After adjusting for additional covariates of family membership, assay plate, BMI, and sex, 12 proteins showed significant diagnosis-age interactions (Table 3; Figure 1). None of these proteins overlapped with molecules found to be significantly different in the comparison of all ASD and control subjects (Table 2). The most significant divergences in trajectories were observed for matrix metalloproteinase 7 (MMP-7) (\( P = 0.005 \); increasing slope), adiponectin (\( P = 0.007 \); increasing slope) and transferrin (\( P = 0.012 \); decreasing slope). The most profound ratiometric differences across age groups were seen for haptoglobin, cancer antigen 19–9 (CA-19-9), thyroglobulin (TG) and C-reactive protein (CRP), which were present at approximately 50% of control levels in the youngest age group (<9 years) and were increased by more than 200% compared to controls in the highest age group (>13 years). Four molecules (insulin-like growth factor binding protein 5 (IGFBP5), transferrin, neuropilin-1, creatine kinase-MB (CK-MB)) showed the opposite trajectory with respect to typical molecular levels, with higher levels seen in the youngest group and lower levels in the oldest group.

### Table 1 Multiplex immunoassay analysis identification of proteins significantly altered in autism spectrum disorders (ASD)

| Analytes                                             | \( P \) value | Fold change* |
|------------------------------------------------------|---------------|-------------|
| Tamm-Horsfall urinary glycoprotein                   | 0.004         | 1.18        |
| Interleukin-3                                        | 0.010         | 0.79        |
| von Willebrand factor                                | 0.023         | 1.16        |
| Interleukin 12 subunit p40                           | 0.025         | 0.87        |
| Tyrosine kinase with Ig and EGF homology domains 2   | 0.033         | 1.09        |
| Tumor necrosis factor beta                           | 0.034         | 1.18        |
| Interleukin-13                                       | 0.038         | 0.86        |
| Macrophage derived chemokine                         | 0.042         | 0.92        |
| Stem cell factor                                     | 0.050         | 0.89        |

*Geometric means were used to calculate fold changes (ASD/control) in ASD individuals (\( n = 37 \)) compared to control (\( n = 37 \)) subjects. There were no significant differences in age (ASD = 10.9 ± 3.4 years; control = 10.3 ± 3.0 years) or body mass index (BMI) (ASD = 18.0 ± 3.5 kg/m², control = 17.7 ± 3.1 kg/m²). Autism Spectrum Quotient (AQ) scores were significantly different (ASD = 92.0 ± 20; control = 43.9 ± 18; \( P < 0.001 \)). See Table 2 for more detailed demographics. Demographics are reported as mean ± standard deviation.
Correlations of molecules with significant diagnosis-age interactions

Spearman rank correlation testing showed that the levels of 11 out of the 12 molecules with significant age-diagnosis interactions were also significantly correlated with at least one other molecule (Figure 2). TRAIL-R3 was the only protein that was not correlated with at least one other. Neuropilin 1 had the highest Spearman correlation coefficient and most significant correlations with the proteins transferrin ($R = 0.779$, $P = 1.36E-08$) and thyroglobulin ($R = -0.618$, $P = 4.62E-05$). Also, adiponectin, transferrin and neuropilin 1 showed the greatest number of connections by having significant correlations with four other proteins.

Pathway analysis

The UniProt accession codes of all 12 proteins were uploaded into the Ingenuity Pathways Knowledge Base (IPKB; www.ingenuity.com) to identify the most over-represented pathways associated with the dataset (Table 4). This showed that the diseases most significantly associated with these proteins were hematological diseases ($P < 0.001$) and endocrine system disorders ($P < 0.001$). Both of these categories were linked to changes in adiponectin, creatine kinase-MB, C-reactive protein, haptoglobin, matrix metalloproteinase 7 and transferrin, although interferon inducible T cell α-chemoattractant (ITAC) was associated specifically with hematological disease and thyroglobulin was specifically related to endocrine system disorders. The most significant canonical pathway associated with the proteins was acute phase response signaling ($P < 0.001$), based on changes in C-reactive protein, haptoglobin and transferrin.

Discussion

This is the first proteomic profiling study aimed at identifying age-related serum biomarker changes in young

| Table 2 Demographic information after separation of autism spectrum disorder (ASD) and control subjects according to age range |
|-------------------------------|-----------------|-----------------|-----------------|
| Diagnosis                    | <9 years ASD    | Control ASD     | 9 to 13 years ASD | Control ASD     | >13 years ASD   | Control ASD     |
| N (M/F)                      | 12 (11/1)       | 11 (9/2)        | 17 (14/3)        | 22 (20/2)       | 8 (8/0)         | 4 (4/0)         |
| AD/PDD-NOS                   | 7/5             | NA              | 11/6             | NA              | 3/5             | NA              |
| Age                          | 7.2 ± 1.2   | 6.8 ± 1.6       | 11.2 ± 1.0       | 11.0 ± 1.3      | 15.8 ± 1.7      | 15.4 ± 1.0      |
| BMI                          | 15.9 ± 1.3     | 16.1 ± 1.7      | 17.6 ± 2.1       | 17.5 ± 2.4      | 22.2 ± 4.6      | 23.0 ± 4.0      |
| Height                       | 128 ± 10       | 127 ± 9         | 154 ± 7          | 148 ± 11        | 173 ± 9         | 178 ± 8         |
| Weight                       | 26 ± 5          | 26 ± 6          | 42 ± 8           | 39 ± 10         | 67 ± 19         | 73 ± 12         |
| AQ (Total)                   | 95 ± 16         | 44 ± 23         | 91 ± 22          | 46 ± 17         | 90 ± 21         | 33 ± 11         |

*aDemographic variables are listed as mean ± standard deviation. AD, autistic disorder; AQ, Autism Spectrum Quotient; BMI, body mass index; PDD-NOS, pervasive developmental disorder; not otherwise specified.

| Table 3 Multiplex immunoassay analysis identification of proteins with significant age-diagnosis interactions |
|-------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Analytes                      | Interaction $P$ value | Fold change $a$ | <9 years | 9 to 13 years | >13 years |
| Haptoglobin (HP)              | 0.021            | 0.36            | 1.20     | 2.83           | 0.96           | 2.45           |
| Cancer antigen 19–9 (CA-19-9) | 0.046            | 0.59            | 1.17     | 2.35           | 0.96           | 2.45           |
| Thyroglobulin (TG)            | 0.021            | 0.32            | 1.35     | 2.39           | 0.96           | 2.45           |
| C-Reactive Protein (CRP)      | 0.014            | 0.51            | 1.90     | 2.35           | 0.96           | 2.45           |
| TRAIL-R3 (TR3)                | 0.034            | 0.86            | 0.81     | 1.31           | 0.96           | 2.45           |
| Adiponectin (ADIP)            | 0.007            | 0.80            | 0.81     | 1.25           | 0.96           | 2.45           |
| Matrix metalloproteinase 7 (MMP-7) | 0.005          | 0.82            | 1.07     | 1.23           | 0.96           | 2.45           |
| Interferon inducible T cell α-chemoattractant (ITAC) | 0.035          | 0.66            | 0.86     | 1.21           | 0.96           | 2.45           |
| Insulin-like growth factor binding protein 5 (IGFBP5) | 0.027          | 1.23            | 0.95     | 0.87           | 0.96           | 2.45           |
| Transferrin (TF)              | 0.012            | 1.28            | 0.89     | 0.86           | 0.96           | 2.45           |
| Neuropilin-1 (NP1)            | 0.020            | 1.24            | 0.92     | 0.83           | 0.96           | 2.45           |
| Creatine kinase-MB (CK-MB)    | 0.022            | 1.50            | 0.94     | 0.83           | 0.96           | 2.45           |

*aThe data obtained for all subjects were partitioned into the indicated age bins and geometric means were used to calculate fold changes (autism spectrum disorder/control).
Figure 1 Age-dependent changes in expression of serum proteins in 4- to 18-year-old autism spectrum disorder (ASD) subjects compared to matched sibling controls. Protein concentrations were plotted against age after loge transformation, and a linear regression was fit in ASD subjects (orange) and sibling controls (blue). The abbreviations are as described in Table 3.

Figure 2 Diagram showing significant correlations of protein levels. The coefficient (R) is given above each connection and the width of the connections are inversely proportional to the P value. Red and green connections denote positive and negative correlations, respectively. The abbreviations are as described in Table 3.
Acute phase response 2.56E-04 3/172

divided by the total number of molecules in that pathway. 
canonical pathways represents the number of molecules from the data set determined as described in the Materials and Methods section. The interactions were uploaded into Ingenuity Pathways Knowledge Base (IPKB), and the most over-represented diseases and canonical pathways were hematological disease 1.60E-05 to 1.64E-02

P value Ratio

Table 4 In-silico pathway analysis of proteins with significant diagnosis-age interactions

| Top diseases* | P value | Molecules |
|---------------|---------|-----------|
| Hematological disease | 1.60E-05 to 1.64E-02 | ADIP, CK-MB, CRP, HP, ITAC, MMP-7, TF |
| Endocrine system disorders | 9.51E-05 to 3.71E-02 | ADIP, CK-MB, CRP, HP, MMP-7, TF, TG |

| Top canonical pathway | P value | Ratio |
|-----------------------|---------|-------|
| Acute phase response | 2.56E-04 | 3/172 |

*UniProt accession codes of all 12 proteins with significant diagnosis-age interactions were uploaded into Ingenuity Pathways Knowledge Base (IPKB), and the most over-represented diseases and canonical pathways were determined as described in the Materials and Methods section. The abbreviation of protein names are as indicated in Table 3. The ratio for canonical pathways represents the number of molecules from the data set divided by the total number of molecules in that pathway.

ASD subjects. In addition, we used well-matched non-affected siblings, allowing us to detect changes related specifically to the manifestation of ASD as a clinical state. Using multiplex immunoassay analysis of 208 molecules we identified significantly different age-dependent trajectories in the levels of 12 proteins in ASD individuals compared to unaffected sibling controls. The most significant canonical pathway associated with the age-dependent changing proteins was acute phase response, consistent with known alterations in immunological and inflammatory functions in ASD individuals [19,20]. A literature review by Rossignol and Frye highlighted 10 studies that reported an increase in prevalence of autoimmune disorders in family members of children with ASD [21], and another study has linked perturbed immune function in young autism children to gastrointestinal disturbances [22]. In addition, changes in other proteins were consistent with previous reports related to alterations in metabolism [23] and mitochondrial function [24]. Furthermore, Adams and coworkers have comprehensively reviewed the link between autism and metabolic disturbances in young and adult autistic patients [25]. Interestingly, another study showed that treatment of autism patients with pioglitazone resulted in improvement of some symptoms, with a stronger effect in younger patients [26]. This is the first report showing that changes in these molecules occur in an age-dependent manner in ASD individuals. In addition, our findings suggest that pubertal status may be an important factor to take into consideration after identifying opposing directional changes in the oldest and youngest age groups in ASD compared to unaffected individuals.

It is likely that the significantly different trajectories in the inflammation- and metabolism-related molecules with age in ASD are linked at a fundamental level [27]. For example, C-reactive protein and haptoglobin, which both increased with age in the ASD subjects, are components of the acute phase response, although these same proteins have also been used as biomarkers for immune disorders and metabolic syndrome [28,29]. We also found increased levels of TRAIL-R3, which has been linked to inflammation by regulation of apoptotic processes in immune cells [30] and also to the loss of insulin-producing pancreatic beta cells in type 1 diabetes mellitus [31]. Likewise, we found increased levels of matrix metalloproteinase (MMP) 7 in the higher age group of ASD individuals, suggestive of an inflammatory phenotype. MMPs play a pivotal role in the pathogenesis of autoimmune and inflammatory conditions such as arthritis, atherosclerosis, pulmonary emphysema and endometriosis [32]. In addition, changes in the MMPs have been linked to metabolic diseases including type 2 diabetes mellitus [33].

We also found higher levels of adiponectin with increasing age in ASD individuals compared to a decrease with age seen in the control subjects. The finding of lower levels of adiponectin in the younger age groups of ASD patients is consistent with the findings of Shimizu et al., which showed decreased levels of this protein in ASD subjects compared to controls at an average age of 12 years old [34]. Adiponectin is involved in the control of fat metabolism and insulin sensitivity. Normally, low levels of this protein have been used as a biomarker for oxidative stress, diabetes and a risk factor for metabolic syndrome [35,36]. Therefore, this finding may be in contrast with the reported higher incidence of these conditions in ASD individuals [37,38]. However, this could also be due to the fact that most previous studies have not accounted for any differences in age-related trajectories. In line with this, we also found decreased levels of insulin-like growth factor binding protein 5, which is known to be involved in cell proliferation, differentiation and apoptosis [39], in diabetes and other metabolic conditions [40]. The finding that thyroglobulin levels were increased with age in ASD individuals may have metabolic links as this protein is an essential autocrine regulator of physiological thyroid follicular function that counteracts the effects of thyroid stimulating hormone [41]. Variations in thyroglobulin are associated with susceptibility to autoimmune thyroid disease type 3, which include Graves’ disease and Hashimoto thyroiditis [42].

Other potential markers of inflammation or immune function that were increased with age included cancer antigen 19–9 (CA-19-9). Although CA-19-9 has been mainly associated with pancreatic cancer [43], it has also been used a biomarker of pancreatic tissue damage as seen in type 2 diabetes and other metabolic disorders [44]. Likewise this marker is elevated in ASD individuals who have insulin resistance [45], suggesting that the ASD individuals in this study may become more susceptible to such disorders after puberty. This is consistent with the increased prevalence of metabolic conditions in
young ASD individuals compared to the general public [46]. We also found high levels of creatine kinase-MB at younger ages, consistent with the findings of a previous study in children with ASD [47]. However, we found that the levels of creatine kinase decreased with age, which suggests that progressive effects may occur in energy metabolism or related pathways in ASD. This could be linked to mitochondrial dysfunction and oxidative stress that has been associated with the etiology of autism [21].

The multiplex immunoassay profiling analysis also led to identification of decreased levels of neuropilin 1 in young ASD individuals compared to controls. The neuropilin protein family has been implicated in the embryonic development of neural and vascular systems, and regulation of many processes in adults, such as angiogenesis, the vascular system and the immune response [48]. This is in line with previous reports showing effects on both of these pathways in ASD subjects [7-10,49]. Effects on the vascular system can be reflected clinically by an abnormal blood flow. Therefore, it is interesting that neuroimaging studies have identified changes in blood flow in and between certain brain regions of individuals with ASD when tested under resting and active conditions [50,51]. It should be noted that we did not find any age-related changes in the levels of BDNF as described in previous studies [12]. However, this could be due to the fact that such changes have only been described for individuals with ASD in the 0 to 9 years age range and the present study only considered participants older than 4 years of age.

Conclusions

One limitation of this study was the potential bias in the molecular class of the investigated molecules. This procedure was based on the commercial availability of a multiplexed immunoassay platform and did not specifically target proteins of other functional classes. Therefore, it is possible that a different selection of molecules would lead to different conclusions from those drawn in this study. Another limiting factor was the small number of clinical serum samples tested using the multiplex analysis. This was due to the rarity of such samples that could be obtained using strict standard operating procedures from both ASD individuals and matched sibling controls. In addition, the samples used in this study were obtained using matched ASD individuals and controls sampled at a single time point. It would be more accurate to repeat the study under prospective conditions in which multiple samples are taken from the same subjects over time, although this is most likely impractical and will result in a high drop-out rate. Finally, the current findings should be considered as preliminary as we did not correct $P$ values from the molecular analysis studies for multiple hypothesis testing. However, there have been no previous proteomic profiling studies carried out in young autism patients that have led to identification of large effects because well-controlled studies using such well-characterized patients are rare. In conclusion, we have identified 12 serum proteins involved in inflammation and metabolic dysfunction that appear to show different trajectories in ASD individuals compared to controls. The predominant effect appeared to be an age-related increase in inflammation and metabolic dysfunction. Future research in this area should incorporate the use of follow-up data from analysis of separate cohorts to confirm these findings. The study of younger subjects in prospective studies would provide further insight into the role of these proteins in ASD and enable development of more accurate, early diagnostic tests. Also, sampling from the same individuals over time will help to determine the true age-dependency of these serum protein expression changes. Furthermore, association studies that compare the protein readings with the time course of symptoms and other read-outs, such as those from functional imaging analyses [52], will be helpful in increasing our understanding of the changes which occur in ASD at different developmental stages. We anticipate that the development and application of biomarker test panels based on the current findings will lead to earlier and more accurate diagnosis and could also lead to the development of much-needed novel therapies for individuals with these conditions.

Abbreviations

AD: Autism disorder; ASD: Autism spectrum disorder; AQ: Autism Spectrum Quotient; BDNF: Brain-derived neurotrophic factor; BMI: Body mass index; CA-19-9: Cancer antigen 19–9; CK-MB: Creatine kinase-MB; CILA: Clinical laboratory improvement amendments; CMO: Commissie Mensgebonden Onderzoek; CRP: C-reactive protein; EGF: Epidermal growth factor; IGF-BPs: Insulin-like growth factor binding protein 5; IPK: Ingenuity Pathways Knowledge Database; ITAC: Interferon inducible T cell a-chemoattractant; MAP: Multi-analyte profiling; mRNA: Messenger ribonucleic acid; MMP: Matrix metalloproteinase; NMR: Nuclear magnetic resonance; PDD-NOS: Pervasive developmental disorder-not otherwise specified; TG: Thyroglobulin; STARD: Standards for reporting of diagnostic accuracy; TRAIL-R3: Tumor necrosis factor receptor superfamily member 10C.

Competing interests

PCG, HR and SB are consultants for Myriad-RBM. However, this does not interfere with policies regarding sharing of data and materials as specified by the journal.

Authors’ contributions

JMR and PCG carried out the molecular profiling data analyses, interpreted the results, prepared the figures and tables, and wrote the manuscript. JACB and HR wrote the manuscript and carried out editing. JG, NR and BF designed the clinical studies and edited the manuscript. JKB and SB conceived the study, interpreted the results and edited the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This work was funded by Autism Speaks Grant #66009, EU FP7 TACTICS - Translational Adolescent and Childhood Therapeutic Interventions in Compulsive Syndromes. Grant Nb. Project number 278948, the Dutch Fund for Economic Structure Reinforcement (FES), under grant agreement number 0908 (NeuroBasic PharmaPhenomics project), by de Hersenstichting.
Netherlands (grant 15F.07) to Jan Brietelaar and the Netherlands Organization for Scientific Research (NWO, Veni grant to Nanda Rommelse).

Author details
1Department of Chemical Engineering and Biotechnology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QT, UK. 2Department of Cognitive Neuroscience, Donders Institute of Brain, Cognition and Behaviour, Radboud University Nijmegen Medical Centre, Geert Grooteplein-Noord 21, Nijmegen 6525 EZ, The Netherlands. 3Department of Psychiatry, Donders Institute of Brain, Cognition and Behaviour, Radboud University Nijmegen Medical Centre, Geert Grooteplein-Noord 21, Nijmegen 6525 EZ, The Netherlands. 4Department of Genetics, Donders Institute of Brain, Cognition and Behaviour, Radboud University Nijmegen Medical Centre, PO Box 9101, Nijmegen 6500 HB, The Netherlands. 5Department of Neuroscience, Erasmus Medical Centre, ‘s-Gravenhijkwal 230, Rotterdam 3015 CE, The Netherlands.

Received: 1 May 2013 Accepted: 11 July 2013

References
1. Fecteau S, Mottron L, Berthiaume C, Barack JA: Developmental changes of autistic symptoms. Autism 2003, 7:255–268.
2. Shattuck PT, Seltzer MM, Greenberg SB, Ormond GI, Bolt D, King S, Lounds J, Lord C: Change in autism symptoms and maladaptive behaviors in adolescents and adults with an autism spectrum disorder. J Autism Dev Disord 2007, 37:1735–1747.
3. Esbensen AJ, Seltzer MM, Lam KS, Bodfish JW: Age-related differences in restricted repetitive behaviors in autism spectrum disorders. J Autism Dev Disord 2009, 39:51–66.
4. Anderson DK, Maye MP, Lord C: Changes in maladaptive behaviors from childhood to young adulthood in autism spectrum disorder. Am J Intellect Dev Disabil 2011, 116:381–397.
5. Bastiaansen JA, Thioux M, Nanetti L, van derGaag C, Kettela C, Minderaa R, Keysers C: Age-related increase in inferior frontal gyrus activity and social functioning in autism spectrum disorders. Biol Psychiatry 2011, 69:832–838.
6. Courchesne E, Redcay E, Kennedy DP: The autistic brain: birth through adulthood. Curr Opin Neuro 2004, 17:499–496.
7. Kraus TA, Tager-Flusberg H, Mock J, Dauterive R, Foundas AL: Frontal and occipital asymmetry and volume in boys with autism spectrum disorder. Cogn Behav Neural 2012, 25:186–194.
8. Gremel E, Nethkum B, Schulte-Rüther M, Fink GR, Nickl-Jockschat T, Herpertz-Dahlmann B, Konrad K, Eckhoff SB: Changes in grey matter development in autism spectrum disorder. Brain Struct Funct 2012, 218:292–942.
9. Kraus TA, Silver AM, Dominick KC, Schuring MD, Shaffer N, Lindgren KA, Joseph RM, Tager-Flusberg H: Age-related changes in the anatomy of language regions in autism spectrum disorder. Brain Imaging Behav 2009, 3:51–63.
10. Hardan AV, Libove RA, Keshavan MS, Melhem NM, Minshew NJ: A preliminary longitudinal magnetic resonance imaging study of brain volume and cortical thickness in autism. Biol Psychiatry 2009, 66:320–326.
11. Kurth F, Nurr KL, Woods RP, O’Neill J, Alger JR, Caplan R, McCracken JT, Toga AW, Levitt JG: Diminished gray matter within the hypothalamus in autism spectrum disorders: a potential link to hormonal effects? Biol Psychiatry 2011, 70:278–282.
12. Katoh-Seimba R, Wakako R, Komori T, Shigemi H, Miyazaki N, Ito H, Kumagai T, Tsuzuki M, Shigemi K, Yoshida F, Nakayama A: Age-related changes in DBN1 protein levels in human serum: differences between autism cases and normal controls. Int J Dev Neurosci 2007, 25:367–372.
13. Kubas B, Kulak W, Sobaniec W, Tarasow S, Lebkowska U, Walecki J: Metabolite alterations in autistic children: a 1H MR spectroscopy study. Adv Med Sci 2012, 57:152–156.
14. Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Lewiecki FM, Rothermundt M, Bogerts B, Koethe D, Kranaster L, Ohmann P, Suslow T, McAllister G, Spain M, Barnes A, van Beveren NU, Baron-Cohen S, Steiner J, Torrey FE, Yokken RH, Bahn S: Identification of a biological signature for schizophrenia in men. Mol Psychiatry 2012, 17:494–502.
15. Schwarz E, Guest PC, Rahmoune H, Wang L, Levin Y, Ingdamomukru E, Ruta L, Kent L, Spain M, Baron-Cohen S, Bahn S: Sex-specific serum biomarker patterns in adults with Asperger’s syndrome. Mol Psychiatry 2011, 16:1213–1220.
16. Domenici E, Wille DR, Tzozi F, Pirokpenko I, Miller S, McKeown A, Brittain C, Rajscek D, Giegling I, Turk C, Holdoerfer B, Bullmore ET, Midleton L, Merlo-Pich E, Alexandre RC, Muglia P: Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case–control collections. PLoS One 2010, 5:e9166.
17. Lord C, Rutter M, Le Couteur A: Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994, 24:669–685.
18. Bossuyt PM, Reitsma JB: The STARD initiative. Lancet 2003, 361:21.
19. Onore C, Careaga M, Ashwood P: The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun 2012, 26:383–392.
20. Careaga M, Van de Water J, Ashwood P: Immune dysfunction in autism: a pathway to treatment. Neurotherapeutics 2010, 7:283–292.
21. Rossignol DA, Fywe RE: A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol Psychiatry 2012, 17:389–401.
22. Jyonouchi H, Geng L, Ruby A, Zimmerman-Bier B: Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention. Neuropsychology 2008, 21:57–65.
23. Marzi B, Loizzo AL, Gana G, Curatolo P: Autism and metabolic diseases. J Child Neurol 2008, 23:307–314.
24. Zecavati N, Spence SJ: Neurometabolic disorders and dysfunction in autism spectrum disorders. Curr Neurol Neurosci Rep 2009, 9:129–136.
25. Adams JB, Audhya T, McDonough-Means S, Rubin RA, Quig D, Geis E, Gehin E, Loresto M, Mitchell J, Atwood S, Barnhouse S, Lee W: Nutritional and metabolic status of children with autism vs. neurotypical children, and the association with autism severity. Nutr Metab (Lond) 2011, 8:34.
26. Boris M, Kaiser CC, Goldblatt A, Elice MW, Edelston SM, Adams JB, Feinstein DL: Effect of piroglitazone treatment on behavioral symptoms in autistic children. J Neuroinflammation 2007, 4:3.
27. Sinkhla M, Sharma TK, Mathur K, Rathor JS, Butola V, Gadghok AK, Vardey SK, Sinha M, Kausch GG: Relationship of oxidative stress with obesity and its role in obesity induced metabolic syndrome. Clin Lab 2012, 58:385–392.
28. Vallianou NG, Evangelopoulos AA, Panagiotakos DB, Georgiou AT, Zacharias GA, Vogiatzakis ED, Avgerinos PC: Associations of acute-phase reactants with metabolic syndrome in middle-aged overweight or obese people. Med Sci Monit 2010, 16:CR56–CR60.
29. Bell SA, Faust H, Schindl A, Werner J, Weisser M: Autoantibodies to C-reactive protein (CRP) and other acute-phase proteins in systemic autoimmune diseases. Clin Exp Immunol 1998, 113:327–332.
30. Renshaw SA, Parmar JS, Singleton V, Rowe SJ, Dockrell DH, Dower SK, Bingle CD, Chilvers ER, Whyte MK: Acceleration of human neutrophil apoptosis by TRAIL. J Immunol 2003, 170:1027–1033.
31. Salehi E, Vodgiani M, Massoud A, Keyhani A, Rajab A, Shafaghi B, Gheflati Z, Aboutajazz Z: Increased expression of TRAIL and its receptors on peripheral T-cells in type 1 diabetic patients. Iran J Immunol 2007, 4:197–205.
32. Almallei C, Caruntu ID, Giucă SE, Bitan RA: Matrix metalloproteinases involvement in pathologic conditions. Rom J Morphal Embryol 2010, 51:215–228.
33. Marselli L, Thorne J, Daihya S, Sgro DC, Sharma A, Bonner-Weir E, Weir GC: Gene expression profiles of Beta-cell enriched tissue obtained by laser capture microdissection from subjects with type 2 diabetes. PLoS One 2010, 5:e11499.
34. Fujita-Shimizu A, Suzuki K, Nakamura K, Miyachi T, Matsuhashi K, Kajikura M, Shinmura C, Iwata Y, Suda S, Tsuchiya KI, Matsumoto K, Sugihara G, Iwata K, Yamamoto S, Tsujii M, Sugiyama Y, Takei N, Mori N: Decreased serum levels of adiponectin in subjects with autism. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:455–458.
35. Klünder-Klünder M, Flores-Huerta S, García-Macedo R, Peralta-Romero J, Cruz M: Adiponectin in eutrophic and obese children as a biomarker to predict metabolic syndrome and each of its components. BMC Publ Health 2013, 13:88.
36. Mather KJ, Funahashi T, Matsuzawa Y, Edelstein S, Bray GA, Kahn SE, Crandall J, Marcovina S, Goldstein B, Goldberg R: Diabetes prevention program. Adiponectin, change in adiponectin, and progression to diabetes in the diabetes prevention program. *Diabetes* 2008, 57:980–986.

37. Guevara-Campos J, González-Guavara L, Briones P, López-Gallardo E, Bulán N, Ruiz-Pesini E, Rammarine D, Montoya J: Autism associated to a deficiency of complexes III and IV of the mitochondrial respiratory chain. *Invest Clin* 2010, 51:423–431.

38. Hahn A, Neubauer BA: Autism and metabolic disorders—a rational approach. Z Kinder Jugendpsychiatrie Psychother 2005, 33:259–271.

39. Hwang JR, Huh JH, Lee Y, Lee SI, Rho SB, Lee JH: Insulin-like growth factor-binding protein-5 (IGFBP-5) inhibits TNF-α-induced NF-κB activity by binding to TNFR1. *Biochem Biophys Res Commun* 2011, 405:545–551.

40. Giannini S, Mohan S, Kasuya J, Galli G, LeBon TR, Fujita-Yamaguchi Y: Characterization of insulin-like growth factor-binding proteins produced by cultured fibroblasts from patients with noninsulin-dependent diabetes mellitus, insulin-dependent diabetes mellitus, or obesity. *J Clin Endocrinol Metab* 1994, 79:1824–1830.

41. Suzuki K, Kawashima A, Yoshihara A, Akama T, Sue M, Yoshida A, Kimura HJ: Role of thyroglobulin on negative feedback autoregulation of thyroid follicular function and growth. *J Endocrinol* 2011, 209:169–174.

42. Ban Y, Greenberg DA, Concepcion E, Skrbaneck L, Villanueva R, Torner Y: Amino acid substitutions in the thyroglobulin gene are associated with susceptibility to human and murine autoimmune thyroid disease. *Proc Natl Acad Sci USA* 2003, 100:15119–15124.

43. Fong ZV, Winter JM: Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. *Cancer J* 2012, 18:530–548.

44. Yu H, Li K, Zhang L, Chen H, Bao Y, Jia W: Serum CA19-9 level associated with metabolic control and pancreatic beta cell function in diabetic patients. *Exp Diabetes Res* 2012, 2012:415189.

45. Huang Y, Xu Y, Bi Y, Xu M, Liu J, Wang T, Li M, Chen Y, Liu Y, Huang F, Xu B, Zhang J, Wang W, Ning G: Relationship between CA 19-9 levels and glucose regulation in a middle-aged and elderly Chinese population. *J Diabetes* 2012, 4:147–152.

46. Kohane IS, McMurry A, Weber G, MacFadden D, Rappaport L, Kunkel L, Bickel J, Watanasin N, Spence S, Murphy S, Churchill S: The co-morbidity burden of children and young adults with autism spectrum disorders. *PLoS One* 2012, 7:e33224.

47. Al-Mosalem OA, El-Ansary A, Attas O, Al-Ayadhi L: Metabolic biomarkers related to energy metabolism in Saudi autistic children. *Clin Biochem* 2009, 42:949–957.

48. Uniewicz KA, Fennig DG: Neuropilins: a versatile partner of extracellular molecules that regulate development and disease. *Front Biosci* 2008, 13:4339–4360.

49. Emanuele E, Orsi P, Barale F, di Nemi SU, Bertona M, Politi P: Serum levels of vascular endothelial growth factor and its receptors in patients with severe autism. *Clin Biochem* 2010, 43:317–319.

50. Wilcox J, Tsuang MT, Ledger E, Algeo J, Schnurr T: Brain perfusion in autism varies with age. *Neuropsychobiology* 2002, 46:13–16.

51. Boddart N, Zibovicus M: Functional neuroimaging and childhood autism. *Pediatr Radiol* 2002, 32:1–7.

52. Dichter G5: Functional magnetic resonance imaging of autism spectrum disorders. *Dialogues Clin Neurosci* 2012, 14:319–351.